Figure 5.

Treatment with the EV71-specific antibody from infected CD4^−/− mice reduces the lethality and disease severity of infected B^−/− mice by decreasing tissue viral loads. The (a) survival rates and (b) disease scores of infected B^−/− mice given the control antibody (control Ab; n = 5) from noninfected CD4^−/− mice or the EV71-specific antibody (EV71 Ab; n = 8) from infected CD4^−/− mice are shown. (c) The viral titers in the indicated tissues of B^−/− mice given control antibody (control Ab; n = 4–6) or EV71-specific (EV71 Ab; n = 4–6) antibody 5 days after infection are shown. The data shown in (b) and (c) are the mean values ± or plus SE values (error bars). Survival rates that are significantly different (P < 0.001) by the log-rank test are indicated (§§§). Disease scores that are significantly different (P < 0.01) by the Wilcoxon signed-rank test are indicated (††). Viral titers that are significantly different (P < 0.05) by the Mann-Whitney U test are indicated (∗).